ナノボディ市場レポート：2030年までの動向、予測、競合分析

ナノボディの動向と予測

世界のナノボディ市場は、2024年から2030年までのCAGRが24.7%で、2030年までに推定28億米ドルに達すると予想されています。この市場の主な促進要因は、精密医療への関心の高まりとナノボディ研究開発への支援の高まりです。世界のナノボディ市場の将来は、治療、診断、研究の各市場における機会によって有望視されています。

ナノボディ市場の洞察

Lucintel社の予測によると、多様ながん種の存在感が高まっていることから、予測期間中、モノ特異的ナノボディが高い成長を遂げる見込みです。

この市場の中では、製薬会社によるナノボディ採用の増加により、研究分野が最大のセグメントであり続ける。

北米は、ナノボディ技術に関連する高い認知度により、予測期間中最大の地域であり続ける。

よくある質問

Q1.市場規模は？

A1.世界のナノボディ市場は、2030年までに推定28億米ドルに達すると予想されています。

Q2.市場の成長予測は？

A2.世界のナノボディ市場は、2024年から2030年にかけて24.7%のCAGRで成長すると予想されます。

Q3.市場の成長に影響を与える主な促進要因は？

A3.この市場の主な促進要因は、精密医療への関心の高まりとナノボディ研究開発への支援の高まりです。

Q4.市場の主要セグメントは？

A4.ナノボディ市場の将来は、治療、診断、研究市場に機会があり、有望です。

Q5.市場の主要企業は？

A5.主なナノボディ企業は以下の通り。

• Sanofi
• Merck KGaA
• BIOCYTOGEN
• Proteintech
• Novartis
• GenScript
• Sensei Biotherapeutics
• Beroni
• ExeVir Bio
• Taisho Pharmaceutical

Q6.今後、最大となる市場セグメントは？

A6.Lucintel社の予測では、多様なタイプのがんが増加しているため、予測期間中、モノ特異的ナノボディが高い成長を遂げる見込みです。

Q7.市場において、今後5年間に最大になると予想される地域は？

A7.北米は、ナノボディ技術に関連する高い認知度により、予測期間中最大の地域であり続ける。

Q8.レポートのカスタマイズは可能？

A8.はい、Lucintelは追加費用なしで10％のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界のナノボディ市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界のナノボディ市場動向（2018-2023）と予測（2024-2030）
• 種類別
  • 単一特異性
  • マルチスペシフィック
• 用途別
  • 治療用
  • 診断
  • 調査
• 最終用途別
  • 製薬およびバイオテクノロジー企業
  • 調査
  • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別のナノボディ市場
• 北米のナノボディ市場
• 欧州のナノボディ市場
• アジア太平洋のナノボディ市場
• その他地域のナノボディ市場

第5章 競合の分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
• 世界のナノボディ市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界のナノボディ市場の能力拡大
  • 世界のナノボディ市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• Sanofi
• Merck KGaA
• BIOCYTOGEN
• Proteintech
• Novartis
• GenScript
• Sensei Biotherapeutics
• Beroni
• ExeVir Bio
• Taisho Pharmaceutical

Nanobody Trends and Forecast

The future of the global nanobody market looks promising with opportunities in the therapeutic, diagnostic, and research markets. The global nanobody market is expected to reach an estimated $2.8 billion by 2030 with a CAGR of 24.7% from 2024 to 2030. The major drivers for this market are surging interest in precision medicine and elevating support for nanobody research and development.

A more than 150-page report is developed to help in your business decisions.

Nanobody by Segment

The study includes a forecast for the global nanobody by type, application, end use, and region.

Nanobody Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Mono-Specific
• Multi-Specific

Nanobody Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Therapeutic
• Diagnostic
• Research

Nanobody Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Pharmaceutical & Biotechnology Companies
• Research Laboratories
• Others

Nanobody Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Nanobody Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies nanobody companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the nanobody companies profiled in this report include-

• Sanofi
• Merck KGaA
• BIOCYTOGEN
• Proteintech
• Novartis
• GenScript
• Sensei Biotherapeutics
• Beroni
• ExeVir Bio
• Taisho Pharmaceutical

Nanobody Market Insights

Lucintel forecasts that mono-specific is expected to witness the higher growth over the forecast period due to escalating presence of diverse cancer types.

Within this market, research will remain the largest segment due to growing adoption of nanobodies by pharmaceutical companies.

North America will remain the largest region over the forecast period due to high awareness associated with nanobodies technology.

Features of the Global Nanobody Market

Market Size Estimates: Nanobody market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Nanobody market size by type, application, end use, and region in terms of value ($B).

Regional Analysis: Nanobody market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, end use, and regions for the nanobody market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the nanobody market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the nanobody market size?

Answer: The global nanobody market is expected to reach an estimated $2.8 billion by 2030.

Q2. What is the growth forecast for nanobody market?

Answer: The global nanobody market is expected to grow with a CAGR of 24.7% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the nanobody market?

Answer: The major drivers for this market are surging interest in precision medicine and elevating support for nanobody research and development.

Q4. What are the major segments for nanobody market?

Answer: The future of the nanobody market looks promising with opportunities in the therapeutic, diagnostic, and research markets.

Q5. Who are the key nanobody market companies?

Answer: Some of the key nanobody companies are as follows.

• Sanofi
• Merck KGaA
• BIOCYTOGEN
• Proteintech
• Novartis
• GenScript
• Sensei Biotherapeutics
• Beroni
• ExeVir Bio
• Taisho Pharmaceutical

Q6. Which nanobody market segment will be the largest in future?

Answer: Lucintel forecasts that mono-specific is expected to witness the higher growth over the forecast period due to escalating presence of diverse cancer types.

Q7. In nanobody market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high awareness associated with nanobodies technology.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the nanobody market by type (mono-specific and multi-specific), application (therapeutic, diagnostic, and research), end use (pharmaceutical & biotechnology companies, research laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Nanobody Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Nanobody Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Nanobody Market by Type
  • 3.3.1: Mono-Specific
  • 3.3.2: Multi-Specific
• 3.4: Global Nanobody Market by Application
  • 3.4.1: Therapeutic
  • 3.4.2: Diagnostic
  • 3.4.3: Research
• 3.5: Global Nanobody Market by End Use
  • 3.5.1: Pharmaceutical & Biotechnology Companies
  • 3.5.2: Research Laboratories
  • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Nanobody Market by Region
• 4.2: North American Nanobody Market
  • 4.2.2: North American Nanobody Market by Application: Therapeutic, Diagnostic, and Research
• 4.3: European Nanobody Market
  • 4.3.1: European Nanobody Market by Type: Mono-Specific and Multi-Specific
  • 4.3.2: European Nanobody Market by Application: Therapeutic, Diagnostic, and Research
• 4.4: APAC Nanobody Market
  • 4.4.1: APAC Nanobody Market by Type: Mono-Specific and Multi-Specific
  • 4.4.2: APAC Nanobody Market by Application: Therapeutic, Diagnostic, and Research
• 4.5: ROW Nanobody Market
  • 4.5.1: ROW Nanobody Market by Type: Mono-Specific and Multi-Specific
  • 4.5.2: ROW Nanobody Market by Application: Therapeutic, Diagnostic, and Research

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Nanobody Market by Type
  • 6.1.2: Growth Opportunities for the Global Nanobody Market by Application
  • 6.1.3: Growth Opportunities for the Global Nanobody Market by End Use
  • 6.1.4: Growth Opportunities for the Global Nanobody Market by Region
• 6.2: Emerging Trends in the Global Nanobody Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Nanobody Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Nanobody Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Sanofi
• 7.2: Merck KGaA
• 7.3: BIOCYTOGEN
• 7.4: Proteintech
• 7.5: Novartis
• 7.6: GenScript
• 7.7: Sensei Biotherapeutics
• 7.8: Beroni
• 7.9: ExeVir Bio
• 7.10: Taisho Pharmaceutical